Holen Sie sich die Stockscreener-App
1.29
3.01%
-0.04
Handel nachbörslich:
1.27
-0.02
-1.55%
MAIA Biotechnology Inc Aktie (MAIA) Neueste Nachrichten
MAIA Biotechnology Awards Executive Bonuses After Successful Financing - tipranks.com
MAIA Biotechnology (NASDAQ: MAIA) director receives 27,258 stock options at $1.40 - Stock Titan
MAIA Biotechnology (MAIA) awards director 27,907 options at $1.40 - Stock Titan
MAIA (MAIA) director receives grant of 27,258 stock options - Stock Titan
MAIA Biotechnology (MAIA) director granted 33,748 stock options - Stock Titan
MAIA (MAIA) director receives 28,556 stock options at $1.40 strike - Stock Titan
[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity - stocktitan.net
MAIA Biotechnology (MAIA) awards cash bonuses after recent capital raise - Stock Titan
Noble Financial Maintains MAIA Biotechnology(MAIA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Bond Watch: How does MAIA Biotechnology Inc compare to its peersEarnings Recap Report & Growth-Oriented Investment Plans - baoquankhu1.vn
MAIA Highlights Promising Phase 2 NSCLC Survival Outcomes - tipranks.com
Treasury Yields: Is now the right time to enter MAIA Biotechnology Inc2026 Price Momentum & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
MAIA Biotechnology reports >2-year overall survival for 8 NSCLC patients in Phase 2 THIO-101 - TradingView
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer - The Manila Times
Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer - TradingView
Eight MAIA (NYSE: MAIA) NSCLC patients top two-year survival on Phase 2 regimen - Stock Titan
After prior treatment failed, 8 lung cancer patients lived past 2 years - Stock Titan
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Drops By 26.2% - MarketBeat
MAIA PE Ratio & Valuation, Is MAIA Overvalued - Intellectia AI
MAIA Showcases THIO-101 NSCLC Data at ELCC 2026 - The Globe and Mail
MAIA Biotechnology presents THIO-101 poster showing sustained responses in relapsed NSCLC - TradingView
MAIA Biotechnology (NYSE American: MAIA) presents ELCC 2026 trial poster - Stock Titan
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - finance.yahoo.com
MAIA Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
MAIA Biotechnology, Inc. 2025 Annual 10-K SEC Filing Overview: Private Placements, Warrants, and Equity Transactions - Minichart
MAIA Biotechnology (NYSEAMERICAN:MAIA) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS - marketbeat.com
MAIA Biotechnology 10-K: Operating loss $24.27M, Net loss $22.40M; Cash $8.66M - TradingView
MAIA: Advanced clinical pipeline and $33M capital raise position company for pivotal 2026 milestones - TradingView
MAIA Biotechnology (MAIA) advances ateganosine with Fast Track and Phase 3 NSCLC trial - Stock Titan
Market Review: Will MAIA Biotechnology Inc outperform small cap indexes2026 Market WrapUp & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Fundamentals Check: What are the future prospects of MAIA Biotechnology IncPortfolio Update Report & AI Driven Price Forecasts - baoquankhu1.vn
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Expands By 17.9% - MarketBeat
MAIA Biotechnology (MAIA) Expected to Announce Quarterly Earnings on Friday - Defense World
MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Up 0.7%Still a Buy? - MarketBeat
MAIA Earnings History & Surprises | EPS & Revenue Results | MAIA BIOTECHNOLOGY INC (NYSEARCA:MAIA) - ChartMill
Is the Market Bullish or Bearish on MAIA Biotechnology Inc? - Sahm
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock - Sahm
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - GlobeNewswire Inc.
MAIA Biotechnology Completes $30 Million Public Stock Offering - TipRanks
Maia Biotechnology Inc enters underwriting agreement with Konik Capital PartnersSEC filing - marketscreener.com
Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital PartnersSEC Filing - TradingView
MAIA Biotechnology (NYSE American: MAIA) closes $30M common stock raise - Stock Titan
MAIA Biotechnology Prices $30 Million Offering of 20 Million Shares at $1.50 - TradingView
[424B5] MAIA Biotechnology, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
MAIA Shares Fall After Pricing of $30 Million Public Offering - marketscreener.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
MAIA Biotechnology shares drop 29% on discounted stock offering By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's Pre-Market SessionAdial Pharmaceuticals (NASDAQ:ADIL), Ensys - Benzinga
Cancer immunotherapy firm MAIA raises $30M for trials, costs - Stock Titan
MAIA Biotechnology Prices $30 Mln Public Offering Of Shares At $1.50/shr; Stock Down - Nasdaq
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock - ChartMill
MAIA Biotechnology (NYSE: MAIA) offers common stock and pre-funded warrants - Stock Titan
Cancer immunotherapy developer MAIA plans stock sale to fund trials - Stock Titan
MAIA Should I Buy - Intellectia AI
MAIAMAIA Biotechnology Inc. Latest Stock News & Market Updates - Stock Titan
MAIA Biotechnology Highlights Progress in Phase 3 Oncology Program - TipRanks
MAIA Biotechnology cites Phase 3 momentum for ateganosine, targets $50B immunotherapy market - TradingView
MAIA Biotechnology (NYSE: MAIA) touts Phase 3 NSCLC drug and Fast Track - Stock Titan
MAIA Biotechnology : Shareholder Letter - marketscreener.com
MAIA Biotechnology’s Phase 3 Momentum Demonstrates - GlobeNewswire
0.87%
0.11%
Kapitalisierung:
|
Volumen (24h):